BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Dilon Diagnostics Release: Molecular Breast Imaging Is Superior to Ultrasound and Mammography for the Detection of Breast Cancer


2/14/2012 11:38:04 AM

NEWPORT NEWS, Va., Feb. 14, 2012 /PRNewswire/ -- Dilon Diagnostics -- According to a new study published in the American Journal of Roentgenology (AJR) in January 2012, Molecular Breast Imaging (MBI), also known as Breast-Specific Gamma Imaging (BSGI), can detect cancers missed by the two most common breast imaging studies, mammography and ultrasound. BSGI had the highest overall sensitivity (91%) for breast cancer detection, significantly higher than that of mammography and ultrasound, 74% and 84% respectively. In addition, BSGI was more effective than ultrasound in contributing to patient management when the results of these studies changed the diagnosis provided by mammography.

In this multi-center study of 1042 patients at four institutions, BSGI had an outstanding overall sensitivity of 91% and negative predictive value (NPV) of 96%. The BSGI procedures were conducted with a high-resolution gamma camera, the Dilon 6800®. For patients who had adjunctive imaging procedures with results discordant from those for mammography, BSGI provided higher diagnostic accuracy than ultrasound (77% vs 35%). The group of patients with indeterminate mammograms (BI-RADS 0) received the greatest benefit from use of BSGI. For the BI-RADS 0 patients, BSGI was significantly more likely to contribute to patient management than ultrasound, it was less likely to be negative in cancerous lesions and was less likely to be positive in benign lesions. Interestingly 85% of the patients included in this study had dense breast tissue.

The lead author, Dr. Jean M. Weigert, a radiologist at Bradley Memorial Hospital in New Britain, CT, commented that: "BSGI continuously proves to be a very important diagnostics tool in our facility. In the recently published article BSGI indicated a change in patient management for a greater number of patients, and was typically more effective than ultrasound because of improved specificity and positive predictive values."

Ultrasound does not involve an exposure to radiation. BSGI involves the injection of a dose to the patient that is comparable with or lower than that of other diagnostic imaging procedures. According to RadiologyInfo.org, a website co-developed by the American College of Radiology and Radiological Society of North America, "...there are no known long-term adverse effects from such low-dose exposure." Like mammography, the benefits of BSGI greatly outweigh the risks due to radiation exposure.

About BSGI/MBI

As a follow-up to mammography, BSGI/MBI utilizes the Dilon 6800® Gamma Camera to help physicians more clearly differentiate benign from malignant tissue. To perform BSGI/MBI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than normal healthy cells and generally appear as dark spots on the BSGI/MBI image.

About Dilon Diagnostics

Dilon Diagnostics, a brand of Dilon Technologies Inc., is bringing innovative new medical imaging products to market. Dilon's cornerstone product, the Dilon 6800®, is a high-resolution, small field-of view gamma camera, optimized to perform BSGI/MBI, a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake. Many leading medical centers around the country are now offering BSGI/MBI to their patients, such as Cornell University Medical Center, New York and The George Washington University Medical Center, Washington, D.C. For more information on Dilon Technologies please visit www.dilon.com.

Media contact: Pjerin Luli
P: 757-269-4910
E: pluli@dilon.com

SOURCE Dilon Diagnostics



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->